<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01644149</url>
  </required_header>
  <id_info>
    <org_study_id>PJ-500-07</org_study_id>
    <nct_id>NCT01644149</nct_id>
  </id_info>
  <brief_title>Clinical Trial Assessing the Immunologic Response to a Influenza Vaccine Delivered Using an Jet Injection Device or a Needle Syringe</brief_title>
  <official_title>A Randomized Controlled Clinical Trial Assessing the Immunologic Response to an FDA-approved Influenza Vaccine Delivered Using an FDA-Cleared Jet Injection Vaccine Delivery Device or a Needle and Syringe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PharmaJet, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PharmaJet, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study was to evaluate if administration of a seasonal flu
      vaccine using a jet injector device is comparable to traditional needle and syringe delivery
      for eliciting an immune response. A secondary objective was to compare the safety of the two
      delivery methods.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Needle-free jet injection devices create a fine stream of pressurized liquid that is able to
      deliver vaccines and other pharmaceutical products beneath the skin. Design aspects such as
      quality, pressure, orifice size, angle of injection relative to skin and injection stream
      coherence control the depth to which the product is delivered. This technology provides a
      safer delivery option for patients and healthcare staff by removing the need for needles for
      the administration of vaccines.

      In addition to improved safety, additional benefits of using jet injectors include more
      consistent and reliable dose volume delivery, reduced vaccine waste, diminished need to
      transport large quantities of sharps, reduced risk of needle sticks, syringe reuse, and costs
      associated with sharps waste. Jet injectors offer a needle-free procedure to those
      individuals who are adverse to needles.

      This study compared the efficacy of a disposable syringe jet injection device (Stratis) with
      traditional needle and syringe (NS) administration for the delivery of a trivalent
      inactivated influenza vaccine. Efficacy was evaluated by comparing measures of
      hemagglutination inhibition (HI); specifically GMTs, seroconversion and seroprotection.
      Safety of the two administration devices was evaluated by comparison of incidence of
      solicited local and systemic adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT)</measure>
    <time_frame>28 days</time_frame>
    <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio (GMT with Needle-Free / GMT with Needle and Syringe) antigen will not exceed 1.5 fold.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Percentage of Participants Achieving Seroconversion</measure>
    <time_frame>28 days</time_frame>
    <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With Solicited Local or Systemic Adverse Events</measure>
    <time_frame>4 days</time_frame>
    <description>Vaccine reactogenicity will be collected on a patient-completed diary card daily for seven days post-vaccination. The following adverse events will be solicited on the diary card: injection site tenderness, injection site pain, injection site redness, injection site swelling, injection site itching, injection site bruising, fatigue, muscle aches, headache, decreased appetite, fever, pruritus.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">83</enrollment>
  <condition>Influenza Prophylaxis</condition>
  <arm_group>
    <arm_group_label>Stratis Jet Injector</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using the Stratis Jet Injector</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Needle and Syringe</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using Needle and Syringe</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stratis Jet Injector</intervention_name>
    <description>Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine</description>
    <arm_group_label>Stratis Jet Injector</arm_group_label>
    <other_name>Jet Injector</other_name>
    <other_name>Disposable Syringe Jet Injector</other_name>
    <other_name>DSJI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Needle and Syringe</intervention_name>
    <description>Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine</description>
    <arm_group_label>Needle and Syringe</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>2011-2012 Fluzone trivalent inactivated influenza vaccine</intervention_name>
    <arm_group_label>Needle and Syringe</arm_group_label>
    <arm_group_label>Stratis Jet Injector</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male subjects ages 18 to 59 years

          -  Healthy volunteers

          -  Able to provide informed consent and understand study procedures per ICH/GCP
             guidelines

          -  Plans to remain in study area for length of the trial; able to adhere to study visit
             and follow-up schedule

          -  Able to complete study diary

        Exclusion Criteria:

          -  Unwilling or unable to undergo the two blood draws per protocol

          -  Have received influenza vaccination in the last twelve months

          -  Have received any vaccination in the last month

          -  Currently taking antibiotics, steroids, phenytoin, chemotherapy, or other
             immunosuppressive drugs

          -  Received recent blood, blood products, or parenteral preparations of immunoglobulin
             (within 3 months)

          -  Suffers from allergic reactions to egg, gelatin, or neomycin or has a history of
             anaphylactic shock, asthma, urticaria, or other allergic reactions to vaccinations.

          -  Had any serious adverse event associated with a prior vaccination

          -  Has immunodeficiency or autoimmune disease (including HIV)

          -  History of chronic alcohol abuse

          -  Participating in another study concurrently

          -  Pregnant or breastfeeding during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Perlman, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bel-Rea Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bel-Rea Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>July 16, 2012</study_first_submitted>
  <study_first_submitted_qc>July 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2012</study_first_posted>
  <results_first_submitted>May 1, 2019</results_first_submitted>
  <results_first_submitted_qc>June 18, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 20, 2019</results_first_posted>
  <disposition_first_submitted>March 4, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>March 4, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 12, 2013</disposition_first_posted>
  <last_update_submitted>June 18, 2019</last_update_submitted>
  <last_update_submitted_qc>June 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Jet Injector</keyword>
  <keyword>Stratis®</keyword>
  <keyword>PharmaJet</keyword>
  <keyword>Jet Injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Up to 100 subjects between the ages of 18 and 59 were planned with 83 subjects enrolled and 82 subjects vaccinated. Pre- and post-vaccination serum samples were collected from 78 subjects and were analyzed in the Efficacy population.</recruitment_details>
      <pre_assignment_details>A total of 83 subjects were recruited and 78 (39 Stratis® and 39 NS) completed the study. One Stratis® group subject (subject # 23) discontinued from the study prior to vaccination.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Stratis Jet Injector</title>
          <description>Patients assigned to this arm will receive Fluzone trivalent inactivated influenza vaccine administered using the STRATIS needle-free injection device. Fluzone vaccine (2011-2012 formulation): Patients will receive a single intramuscular injection of 0.5 ml of Fluzone vaccine in the deltoid region.
STRATIS needle-free injection device</description>
        </group>
        <group group_id="P2">
          <title>Needle-Syringe</title>
          <description>Patients assigned to this arm will receive Fluzone trivalent inactivated influenza vaccine administered using a needle and syringe. Fluzone vaccine (2011-2012 formulation): Patients will receive a single intramuscular injection of 0.5 ml of Fluzone vaccine in the deltoid region.
Needle-Syringe</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="39">One subject discontinued prior to vaccination. 28 day serum samples not obtained from 3 subjects.</participants>
                <participants group_id="P2" count="39">28 day serum samples were not obtained from one NS subject.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PharmaJet Stratis Injector</title>
          <description>Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using the Stratis Jet Injector
Stratis Jet Injector: Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
2011-2012 Fluzone trivalent inactivated influenza vaccine</description>
        </group>
        <group group_id="B2">
          <title>Needle and Syringe</title>
          <description>Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using Needle and Syringe
Needle and Syringe: Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
2011-2012 Fluzone trivalent inactivated influenza vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="39"/>
            <count group_id="B2" value="39"/>
            <count group_id="B3" value="78"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT)</title>
        <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio (GMT with Needle-Free / GMT with Needle and Syringe) antigen will not exceed 1.5 fold.</description>
        <time_frame>28 days</time_frame>
        <population>The immunogenicity analyses were conducted using data from subjects in the immunogenicity population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratis Jet Injector</title>
            <description>Patients assigned to this arm will receive Fluzone vaccine administered using the PharmaJet (PJ) STRATIS needle-free injection device.
Fluzone vaccine (2011-2012 formulation): Patients will receive a single 0.5 mL injection of Fluzone vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
          <group group_id="O2">
            <title>Needle and Syringe</title>
            <description>Patients assigned to this arm will receive Fluzone vaccine administered using needle and syringe.
Fluzone vaccine (2011-2012 formulation): Patients will receive a single 0.5 mL injection of Fluzone vaccine in the deltoid region.
Needle-Syringe.</description>
          </group>
        </group_list>
        <measure>
          <title>Anti Influenza Hemagglutination Inhibition (HAI) Antibody Geometric Mean Titers (GMT)</title>
          <description>The GMT criterion for non-inferiority for the upper limit of the 95% CIs of the GMT ratio (GMT with Needle-Free / GMT with Needle and Syringe) antigen will not exceed 1.5 fold.</description>
          <population>The immunogenicity analyses were conducted using data from subjects in the immunogenicity population.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/ H1N1 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="1.19"/>
                    <measurement group_id="O2" value="3.49" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A H1N1 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.19" spread="0.98"/>
                    <measurement group_id="O2" value="6.13" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/ H3N2 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" spread="1.30"/>
                    <measurement group_id="O2" value="3.49" spread="1.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2 Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.31" spread="1.28"/>
                    <measurement group_id="O2" value="6.14" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.57" spread="0.51"/>
                    <measurement group_id="O2" value="2.53" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B Day 28</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.17" spread="1.00"/>
                    <measurement group_id="O2" value="4.17" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Percentage of Participants Achieving Seroconversion</title>
        <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
        <time_frame>28 days</time_frame>
        <population>Seroconversion against the hemagglutinin antigens contained in the vaccine were assessed in the Immunogenicity Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratis Jet Injector</title>
            <description>Patients assigned to this arm will receive Fluzone vaccine administered using the PJ STRATIS needle-free injection device.
Fluzone vaccine (2011-2012 formulation): Patients will receive a single 0.5 mL injection of Fluzone vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
          <group group_id="O2">
            <title>Needle and Syringe</title>
            <description>Patients assigned to this arm will receive Fluzone vaccine administered using needle and syringe.
Fluzone vaccine (2011-2012 formulation): Patients will receive a single 0.5 mL injection of Fluzone vaccine in the deltoid region.
Needle-Syringe.</description>
          </group>
        </group_list>
        <measure>
          <title>The Percentage of Participants Achieving Seroconversion</title>
          <description>Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (&lt;1:10), attainment of a post-immunization titer of ≥1:40.</description>
          <population>Seroconversion against the hemagglutinin antigens contained in the vaccine were assessed in the Immunogenicity Population.</population>
          <units>Percentage of Subjects Seroconverted</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>A/H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5"/>
                    <measurement group_id="O2" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>A/H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7"/>
                    <measurement group_id="O2" value="85.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.0"/>
                    <measurement group_id="O2" value="65.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With Solicited Local or Systemic Adverse Events</title>
        <description>Vaccine reactogenicity will be collected on a patient-completed diary card daily for seven days post-vaccination. The following adverse events will be solicited on the diary card: injection site tenderness, injection site pain, injection site redness, injection site swelling, injection site itching, injection site bruising, fatigue, muscle aches, headache, decreased appetite, fever, pruritus.</description>
        <time_frame>4 days</time_frame>
        <population>Data included in the analysis were collected on a 4-Day Diary Card from the safety population and grade &gt;1.</population>
        <group_list>
          <group group_id="O1">
            <title>Stratis Jet Injector</title>
            <description>Patients assigned to this arm will receive Fluzone vaccine administered using the PJ STRATIS needle-free injection device.
Fluzone vaccine (2011-2012 formulation): Patients will receive a single 0.5 mL injection of Fluzone vaccine in the deltoid region.
PJ STRATIS needle-free injection device</description>
          </group>
          <group group_id="O2">
            <title>Needle and Syringe</title>
            <description>Patients assigned to this arm will receive Fluzone vaccine administered using needle and syringe.
Fluzone vaccine (2011-2012 formulation): Patients will receive a single 0.5 mL injection of Fluzone vaccine in the deltoid region.
Needle-Syringe.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With Solicited Local or Systemic Adverse Events</title>
          <description>Vaccine reactogenicity will be collected on a patient-completed diary card daily for seven days post-vaccination. The following adverse events will be solicited on the diary card: injection site tenderness, injection site pain, injection site redness, injection site swelling, injection site itching, injection site bruising, fatigue, muscle aches, headache, decreased appetite, fever, pruritus.</description>
          <population>Data included in the analysis were collected on a 4-Day Diary Card from the safety population and grade &gt;1.</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bruising</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased Appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pruritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Complaints were solicited from subjects in the safety population following vaccination: pain, tenderness, itching, redness, swelling, and bruising at the vaccination site. Local and systemic study injection reactions were monitored for 4 days post injection.</time_frame>
      <desc>Solicited adverse events were those events specifically sought for and recorded by the subject in the 4-Day Diary Card.
The denominators were determined for each individual AE for each summary window (Day 0-4). Subjects in Safety Populations were excluded from the denominator if there was no data captured for the AE within summary window.</desc>
      <group_list>
        <group group_id="E1">
          <title>PharmaJet Stratis Injector</title>
          <description>Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using the Stratis Jet Injector
Stratis Jet Injector: Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
2011-2012 Fluzone trivalent inactivated influenza vaccine</description>
        </group>
        <group group_id="E2">
          <title>Needle and Syringe</title>
          <description>Single intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine using Needle and Syringe
Needle and Syringe: Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
2011-2012 Fluzone trivalent inactivated influenza vaccine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (14.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tenderness</sub_title>
                <description>Local Adverse Reaction within 4 days of vaccination and Grade of &gt;=1</description>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <description>Local symptoms at injection site within 4 days of vaccination with Grade of &gt;=1</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <description>Local event occurring within 4 days of vaccination and Grade of &gt;=1</description>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <description>Local event occurring within 4 days of vaccination and Grade of &gt;=1</description>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <description>Local event occurring within 4 days of vaccination and Grade of &gt;=1</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bruising</sub_title>
                <description>Local event occurring within 4 days of vaccination and Grade of &gt;=1</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Aches</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marilyn Dysart, Clinical Affairs Manager</name_or_title>
      <organization>PharmaJet, Inc.</organization>
      <phone>720-214-9399</phone>
      <email>marilyn.dysart@pharmajet.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

